Effectiveness, safety, and predictors of response to hyaluronic acid in refractory adolescent patellofemoral pain syndrome: preliminary data from a real-world cohort study
Adolescent patellofemoral pain syndrome (APFPS) is a common potentially persistent condition with limited therapeutic options. Intra-articular (IA) hyaluronic acid (HA) injections may provide analgesic benefit, but their use in adolescents remains largely unexplored. This study aimed to evaluate the effectiveness, safety, and predictors of response to HA injection in adolescents with refractory APFPS. Retrospective observational study including adolescents aged 10–18 years with APFPS refractory to first-line management, treated with at least one IA HA injection between January 2019 and June 2025. Data were derived from routine clinical practice with prospectively collected standardized assessments. Treatment effectiveness at 6 months was evaluated using a 5-point Likert scale (0 = not effective to 4 = very effective) and dichotomized into responders (scores 3–4) and non-responders (scores 0–2). Secondary outcomes included “pain-free knee” status, return to sport, and safety. Factors associated with response were explored using univariate and multivariate analyses. 44 adolescents were included (mean age 13.5 ± 1.6 years; 88.6% female). At 6 months, 35 patients (79.5%) were classified as responders. A “pain-free knee” was reported by 40.9% of patients, and 96.9% of evaluable patients returned to sport, including 74.2% at their pre-symptom level. The procedure was well tolerated. In multivariate analysis, regular analgesic use (OR 0.18, 95% CI 0.04–0.82) and emotional disorders (OR 0.22, 95% CI 0.05–0.95) were associated with poorer outcomes. These associations should be interpreted with caution given the small sample and exploratory nature of the analysis. In this first real-world cohort of adolescents with refractory APFPS, IA HA injection was associated with clinically meaningful improvement in most patients and excellent safety. These findings are preliminary, with inherent limitations of a retrospective uncontrolled design, and cannot by themselves support routine clinical use. They provide a rationale for a properly powered randomized controlled trial. 2025-03-FEPALADO
Authors
- Thierry Conrozier (ORCID: https://orcid.org/0000-0003-0353-6292)
- Charlotte Bourgoin
- Jean‐Charles Balblanc
- Anne Lohse
- Léa Da Silva
Institutions
- L'Hôpital Nord Franche-Comté (FR)
Publication Details
- Journal
- BMC Musculoskeletal Disorders
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1186/s12891-026-10723-1
- Primary Topic
- Lower Extremity Biomechanics and Pathologies
- Type
- article
- Field-Weighted Citation Impact
- 0.00